Drugs that block the chemokine monocyte chemoattractant protein 1 (MCP-1 or CCL2) downstream of TWEAK can significantly reduce the growth of CCA xenografts, while TWEAK overexpression promotes the proliferation and collagen deposition of cancer-associated fibroblasts. Here, CCL2 is linked to cholangiocarcinoma.